Marty Reiswig and his experience in a clinical trial for early onset Alzheimer’s

Marty Reiswig is fit and healthy, but every two weeks he is injected with the experimental drug gantenerumab and has monthly MRI scans. He submits to this because a rare genetic mutation runs in his family that predisposes them to early-onset Alzheimer’s disease.

We spoke to him about his experience on the trial, and why he chose to continue trialling the drug even after formal clinical trials were discontinued.

More on this story:

News Feature: Could drugs prevent Alzheimer’s? These trials aim to find out

Resources for those affected by Alzheimer’s:

Alzheimer’s association

Alzheimer’s society

Source link